Quantitative In Vivo Genetic Analysis Reveals Novel Genetic Determinants of Tumor Initiation, Overall Growth, and Exceptional Growth in KRAS-Driven Lung Cancer

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020. CA Cancer J Clin 2020; 70(01): 7-30

[2] Feng RM, Zong YN, Cao SM, Xu RH.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond) 2019; 39(01): 22

[3] Cao M, Li H, Sun D, Chen W.Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40(05): 205-210

[4] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation. Cell 2011; 144(05): 646-674

[5] Consortium APG.AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov 2017; 7(08): 818-831

[6] Wu Y, Liu Z, Xu X.Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020; 40(12): 681-693

[7] Zhang Y, Chang L, Fang W.et al.Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?. Cancer Commun (Lond) 2019; 39(01): 33

[8] Lawrence MS, Stojanov P, Polak P.et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499(7457): 214-218

[9] Greaves M, Maley CC.Clonal evolution in cancer. Nature 2012; 481(7381): 306-313

[10] Winters IP, Murray CW, Winslow MM.Towards quantitative and multiplexed in vivo functional cancer genomics. Nat Rev Genet 2018; 19(12): 741-755

[11] Ben-David U, Beroukhim R, Golub TR.Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer 2019; 19(02): 97-109

[12] Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med 2017; 9(02): 137-153

[13] Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R.et al.Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 2014; 516(7531): 428-431

[14] Rogers ZN, McFarland CD, Winters IP. et al. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 2017; 14(07): 737-742

[15] Cai H, Chew SK, Li C.et al.A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. Cancer Discov 2021; 11(07): 1754-1773

[16] Ciriello G, Cerami E, Sander C, Schultz N.Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012; 22(02): 398-406

RIGHTS & PERMISSIONS

2022 Global Medical Genetics